Previous 10 | Next 10 |
2024-06-18 16:03:19 ET Summary Roche continues to face challenges tied to lackluster revenue and profit outlook, questionable pipeline, and an underperforming diagnostics business. Roche spends aggressively on its pipeline (R&D and M&A) and is more successful than peers in...
2024-06-15 09:00:00 ET Summary There are always opportunities in this market for stocks despite high total market valuation. Gilead Sciences offers strong growth potential with a well-covered dividend yield of 4.8% and a promising pipeline. Enbridge provides stable income with...
2024-06-14 15:55:36 ET More on Bristol-Myers Squibb Company , Gilead Sciences, etc. Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Bristol-Myers...
2024-06-14 15:15:06 ET RBC Capital analyst issues UNDERPERFORM recommendation for GILD on June 14, 2024 12:00PM ET. The previous analyst recommendation was Underperform. GILD was trading at $65.16 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-06-14 15:15:06 ET UBS analyst issues SECTOR PERFORM recommendation for GILD on June 14, 2024 12:00PM ET. The previous analyst recommendation was Sector Perform. GILD was trading at $65.16 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-06-14 15:15:06 ET Evercore ISI analyst issues OUTPERFORM recommendation for GILD on June 14, 2024 11:39AM ET. The previous analyst recommendation was Outperform. GILD was trading at $65.07 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-06-14 11:23:46 ET More on Gilead Sciences Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Gilead Sciences, Inc. (GILD) Jefferies 2024 Global Healthcare Conference Gilead Sciences: Seriously Undervalued At Peak Pes...
– Analysis Shows Manufacturing of Yescarta in Second-Line Treatment of Relapsed/Refractory Large B-cell Lymphoma Can Help Reduce Time from Leukapheresis to Infusion vs. Third-Line+ Treatment – – Data Builds on Previous Evidence on the Association Between Timely In...
2024-06-12 21:00:07 ET Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 01:20 PM ET Company Participants Daniel O'Day - Chairman and Chief Executive Officer Conference Call Participants Salveen Richter - Goldma...
NORTHAMPTON, MA / ACCESSWIRE / June 12, 2024 / Gilead Sciences Luciana Preger credits being exposed to her father's work at a young age with helping inform her own career in medicine. Luciana is a physician with more than 20 years of experience in pharma and she came to Gilead to help transfor...
News, Short Squeeze, Breakout and More Instantly...
– RADIAN’s Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on HIV Across the Region – – RADIAN Will Expand Geographic Focus to Provide Key Populations and Communities Im...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor, Dr. Parsey will continue as Chief Medical Officer until the first quarter of 2025 and support this trans...